All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Plays an essential role for activation and immortalization of human B-cells. Represses transcription of viral promoters TP1 and Cp through interaction with host RBPJ, and inhibits EBNA2-mediated activation of these promoters. Since Cp is the promoter for all EBNA mRNAs, EBNA3A probably contributes to a negative autoregulatory control loop.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-C047Z | Human anti-EBNA3 T cell receptor (LC13), pCDTCR1 | EBV | LC13 | Human | FLRGRAYGL | HLA-B*0801 | Lentiviral | |
TCR-C048Z | Human anti-EBNA3 T cell receptor (CF34), pCDTCR1 | EBV | CF34 | Human | FLRGRAYGL | HLA-B8 | Lentiviral | |
TCR-C049Z | Human anti-EBNA3 T cell receptor (RL42), pCDTCR1 | EBV | RL42 | Human | FLRGRAYGL | HLA-B8 | Lentiviral | |
TCR-C050Z | Human anti-EBNA3 T cell receptor (JL12), pCDTCR1 | EBV | JL12 | Human | FLRGRAYGL | HLA-B8 | Lentiviral |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION